Eli Lilly Stock Jumps on Monster Earnings as Finance Chief Eyes Next Growth Engine — Live Feedhttps://www.live-feeds.com/feed/eli-lilly-stock-jumps-on-monster-earnings-as-finance-chief-eyes-next-growth-engineContinuously updated, source-cited coverage. Eli Lilly Shares Climb After Strong Third-Quarter Earningshttps://www.live-feeds.com/feed/eli-lilly-stock-jumps-on-monster-earnings-as-finance-chief-eyes-next-growth-enginehttps://www.live-feeds.com/feed/eli-lilly-stock-jumps-on-monster-earnings-as-finance-chief-eyes-next-growth-engine#u170771Mon, 02 Nov 2026 17:15:22 +0000Eli Lilly shares climbed following a third-quarter earnings report that surpassed analyst estimates, fueled by resilient demand for the diabetes treatment Mounjaro and the weight-loss drug Zepbound. The pharmaceutical company raised its full-year sales outlook and reported quarterly revenue reaching approximately $24.4 billion. Non-GAAP earnings per share guidance for 2026 was upgraded to a range of $35 to $36. Wall Street responded with strong optimism, lifting the stock following the announcements of robust international growth and regulatory progress across the product portfolio.Why it matt